a, P a , P A ~ n n i ~ ~ a n i u u a s u a n u i n i a ~ ~ a i ~ i s ~ ~ r i i gnssu aaa. . a s u o n ~ n G a ~ i n n i % ~ G i < ~ u

u - dua 3. & a d ~ ~ u u u a ~ d ~ u u i u n r r w ' u d ~ ~ ~ a m a ~

P,

aauasea"u!~uniwGi aaa:GiuinJ~sm~9i~w"uG iau d l 2

~auasmierG!~nwsla:a~i~+u~n~ua~iu~?suaaosi"uu

% a j r n ~ r i i u i d ~ s ~ i l u a i ~ i ~

auu u 5. vl~n~$udLLuadW'uaaunn%a aw%i:Imu

ddd u

.ss%u.aiBa~uas~u~auam%a~:!~wuinn<ibauasi

"bi+ M%3+6ii@il19

6. &add~;~eivlis~li;n aauasdriiuiuiInn

n'asGi%Ggnriau?uds:niuanua aisil:bnunis~a

wam i s e i is ~u aans ~m wyads 5 % ~ abuasuis

. r r ~ n a i g ~ i u i i i k i w 5 n wau%i%uaans~~a:via~un

ailu6u

7. ?Jn u~ u i M ~ ~ H M I ~ L L & Y ~ ~ L L ~ ~ ~

nasgtGn& riauGi"b?ud~:wiu aw%i:aig~::

Gi%~s"~iimaini%aaw"~iadu6u!C !a~uasesaiuaC?

AUI : n e s I n a w i n i ~ n ~ ~ e w i G u , 252 I. m i ~ i ~ b l a m d ~ ~ ~ i i a i ~ i ~ ! w e ~ % u ~ a u 6 ~ w ! ~ e i a ~ i ~ p a " n 100 n i u

~ l i i l nu i lmaB.s d a i u h i u u i In$~9katduumaum ~ U L Z ; A Y 1 ~ L w ~ l ~ ~ l m ~ ~ ~ d i n ~ ~ ~ a G n ~ a i t ; m d s : n u ~ u ~ ~ u ~ i u u i a ~ ~ i a i n

P

d a i u u u~g?inwt a ~ a t a F i ~ l ! T n 1 ~ 6 i u i i ~ aaua~lu I6~ari 6 a ~ z i u i r ( 6 a ~ T a u ~ 9 % 62~1d

n $ u f ~ u i ~ o i i m i i u u n & !&bfi aauaonlui a u a ~ b~uu$l,oi l a , d o beetles, blister beetles,) a ' h u a ~ a ~ g n

a i n a u ( L L ~ J ~ J ~ I U , uaumtwiu ,uauw$~!i) uau LLBJ iiimaamiuiads:uim 3 - 5 a~~uGiaums iaanu u

d

a b u a ~ d o ~ h ( v u a ~ M r ) sa~9';osuugn 3 bbrn~lwimuai~ii iKa aauasniu8 A

at~al%aanu'111?~u (cantharidin) ~ J L ~ ~ ~ I % % % I 3. ntjuGn& a i lun iuAuuna innt jud 2

~ ~ u a ~ u d w u l u u u a ~ T u n ~ d u (Lytta vesicatoria) n ~ u ~ n $ r r t i 7 ~ ~ u B n i ~ n w m t ~ ~ 9 G u u K u m a u m

a is<~ i lun isns t~uds tn in f i~4w 'u~~Bn J s u s t i ~duKuBna:fiuailu~dps~~nin~uiiiKa d i n ~ i l u

d a t l u r r i n i ~ m s u w n u " ~ d s g n s u n ~ u n i ~ ~ i ~ u a t a G m a a i t g m ~ w i a i n i a u r i i u u u ~ ~ ? w : ~ ~ a ; ~ ~ i i u u

l ~ i ~ i n ~ i u u u ~ 1 1 i $ ~ J i I6aari Gniu, L ~ J n iu isn~u~~nu~i?~uuunui !6w"u~ i d u g n i ? w u j

a r f i i h i l i l uduww 9.1 u s n a i n f u a~nwn iyGu~ i lu 4. n ~ u u u ~ a a u a ~ ~ s d ~ u ~ ~ u u ~ ~ n u a i ~ a h . 2 n i s ~ w ~ ~ w $ w " i a i ~ s t u u n i s w " i ~ i u " ~ u ~ ! m i ~ a t

wan oTuarBuw'u$ ~ I ~ $ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ : L W I ~ O ~ M ~ T

ddQ a,

4.1 b ~ t r k ~ a J ~ ~ ? ~ o l ~ l n 1 3 ~ 9 ~ ~ !&Lfi Uf l w ~ ~ ~ n l s < ~ t ~ s l n l s L $ u ~ $ ~ dan<04auLLss ath.4 UflLLflJ ( ! i ~ b a ~ ~ ~ d ~ u ) , u f l u l J ( u f l ~ g J ) , f iaa12~a~ws';o~ $orlPsunws ranzwlulu *

a, a, B LL IJ~J~U (umiBn) s a u n ~ n a i a u u a ~ HJ i o aletbmu dam lud3zLnR!nuG 1 3 aQn dwuilnubnufiuuh

4.2 ~iluaua~ddfTolwinispa"aoi9n~9ia!~i aBu?I?ni 2 aGm i iu Egicauta hirticornis ( m w d 1 ) d

d n R K wann' iqn 2 d Bnat~nduufh.i?.qdi19 us: Mylabris phalerata ( m w A 2) b o i s i o o i u ,a, d

asraGuBn ~ d o ~ n i r i ; ~ u ~ n u n s r ~ " u B n ~ ~ ~ l u s i u ! ~ i i u B w . ~ 2528 a i a u i u nwuaJaJ a . K n y iiu

uu&~iun k !&bri uua~br i i w~adaamssm:dGBn h J & i u a G m Epicauta hiificornk lflub$uiil.a"bilu

u d c 2. uqua 1~aonls:6u. ~mf ls. i ins:gniknasr~~du

ainia%uninm:a"eaaoni~usanCauasd~:iw~her

[Paw e r i ~ w u ~ d ? ~ ~ i P a w e r i ~ i a n ~ u ~ / 1 i G m ~ ~ i l ] .

nini~iQaiweri,~m~~iweri~u.nqs~wwxrniuns:

y n n s n a b a i i n u i b ; 2525. n i w d I 6as$iah : Epicauta hirticol

nisnsu?wuiqiwn5nisiiwweJ" n%wd 3; 3 -4 a - a m w d 2 ~ a s z l ~ u : Mylabris phalerata

Fuaimu 2533; m ani17waseraweri~ian5

sinismgu. uuwyq: nruinuimsmimsuww6;

2533. /

p 9 7 n z <i4plilliTd /

ilisGGsKm&aauasauraynrsr9siw 6. q q ~ i n s Gunhias, 8sn ~un~swod, y.+126i mas:, - =,-

t n l Cun5nilias, s iu r lu f i w 6 ~ ~ . rnsuylnn aniuw~~s5nuimaaa 'a is ism~a

Hepatitis C Virus Infection among Male Inmates at Klong Prem Central Prison: Study on Prevalence

Incidence and Risk Factors

qsu asGGY* uau uwnu"asiw6-J-rswsw' s i a ' l un i I s u u i k 6 - i I r u 6 was6uiiux a in~$u ailGysi%o

wsw'yiw6 ~Ys iu * va: ?aGns l u s a - a, P a , P

* nmuua~oanui~ian~aisisruqu nsuiw oi~ianimsuwnu"ww ns:wsaanisisruqu

u.nGmn:im?ds;aran' siosiunnuds:~wnwuiin~u$&s54uwnu"~uadsmsln~$e!aia&uailuwnu"au$ (HCV) .uinnirldui~awGm~muwnu"iriauiuwnu"~uniulu~isu~i uwnu"uwnu"duimu'syaludst~wfi!wo aiusiu$!6:nwi

tYnsinisG~~$'s HCV aat~u$ouwnu"~ususs~6ssujaia!wu

i ~ m r d n w i Wna iua ia ia~ns$6ss~sa io 689 nu IuL?suiinaisnaosuwnu"dsu uwnu"iluuwnu"as1 5 l i s u

?:Mils W.R. 2544-2545 ImoRumw&iriaua~a~n~a g i l ~ ~ l d ~ . ~ L L R : L P I : L ~ s ~ w ~ ~ ~ ~ ~ I ~ ~ ~ L ~ ~ HCV 6'2~ aahu i~ !aT i i iinn:piilu~uLiosd$uw"ub"n"unis~mb$s HCV h u Stata Intercooled version 6 n i s

~nwidt~u~unisuasbnssnis~n~i~u~u~mwusa~~saujdiiu~ub"~unis~m~C~sa!siua:!a~adu A .asciiunisGuismiuinnm~n~sunisGuisruinis~nwi~~oluuyw6 nsrwsasa is ismy w.n. 2544

s r n n i s i l n w wunis~mt$o HCV +-~uau 309 q i n 687 s i o i%aLilunaiu;n 44.85% [95%

Confidence Interval, CI; 41.20-48.5781 M&uin?nmu 1.740 ~nna- tau wu$inL<s HCV s i u

lnri 106 n o 8 a L i l u q ~ i n i s & 73.08 s ynns-9 [95% CI; 59.88-88.44% PY] ~ l u g o ~ i u s d d

~ o h 6 ~ w i ~ a i i G r n s G m d s HCV l u t j&ssQa iu uinni;iinsi:MCnisnmnso as4aGn!dufiij'ids:TGad

u i ~ a w l m i n ~ G i ~ r i u d i a s s u u s i n m s i m u i ~ G i ~ B u d i a s s u u ~ n G u n i u u i i s n i u ~ilu~?.a"uibaw?imimbiTi

b ~ u u i u n a i 7 9 dd~ :~~bnu~un i~~ i~mn is? imu i r i au6as%ww (Adjusted odd ratio, pc 0.01 )

False Positive Anti-HIV Screening Test; A Retrospective Study of Anti-HIV Confirmation During 1 992-200 1

a- P a - a

a m u u ~ s u ~ w u i n i a a ~ a i a i s m q ~ nsuf nu in ian in i svwnu"

uwgi n ism- las~~s~n ia~m~$ubas i !a? - 1 msi iaadl ju2in is iiiil?uniams2sf~s<uynna{d

i [s~u~$uslsi~Pms~sKmnaas dsn'usms2siuuirwam ns:ws~saiaismqul6aun~~uanisdljuT w.n.

2 539 %~msas~u~u%me~asas~ i6au^a"saaas~mnaus 2 -3 i~Imulallsi~"bsasZufiu6au Western blot & + A 8

~ I ~ ~ I ~ ~ ~ ~ ~ ~ & ~ ~ ~ ~ ~ ~ ~ \ W W R ~ ~ ~ ( ~ ~ U S ~ I U ~ B Y 10 ~WWIUUI b d ~ ~ n ~ ~ m s i w ~ u 2 n d ~ a ~ d w u

91nizBna-1 ~iluniadnwiuuuCuunklnul.a"Gu y awaas~siuGuniui iowau-rnainfPns~a B ~nnsus~~a:~sasasiu~uinsu~nuiniaminiswnef~~at~n~a"~iu s:~-iis w.n. 2535-2544 ~smaas

Zufiuhufi5ui2lurl;uu~sauiun'un: Western blot 3 ~ n s i t ~ n i s ~ d ~ u u ~ ~ d a s u ~ s K m s i n s ~ s iuGuwa

u2nmud2ab2aiu's~almul.a" Chi-square for trend

prani3dn~i n a a ~ ~ w u i n i ~ m s " n ~ s a ~ w w u " ~ ~ a ~ ~ n ~ a " ~ i u l s s " u ~ n i s a s ~ a ~ u ~ u n i s ? i m ~ ~ a ~ a s i ~ o i ~ ~ r i

baswuimsa2u 88.576 s i u aaiugar 8.858 s i u l i 'wau2nms~ 82.360 a iu (92.98%) n l d w a W l 6

1.357 (1.53%) vataa2s iuu i i l6waau 4.875 ( 5 4 9 % ) $ s b i l u w a u 2 n d a a u ~ u n i ~ a s ~ s ~ m n ~ u s 2

< i u ~ u ~ s a s a a ~ u ~ u a : a i l a w.n. 2535-2539 i k u u u (r.0.972) ~ ~ h a m a s s : ~ i i s w.n. 2539-2544 3

(r=O.770) ~uui~:d~~u~~riuuas~msimsasbue~"uwauan~~u~u ( (2 for tend = 38.03, p<0.001)

C I w w I nr ~ ~ W P S R L U W ~ T ~ R D O I L I T L ~ ~ U U ~ L V I T ~ ~ J ~ ~ : ~ U ~ T : ~ J I ~ 2 . 6 w $n in lnu~~ i~&n i~ w a w P ~ ~ w w n k i n m i u u ? ~ ~ m u i ~ i ~ ~ ~ ~ i m r n r p ~ ~ i f a ~ ~ d ~ ~ ~ ~ ~ ~ a ~ ~ ~ i u ~ ~ u $ i a u

V P a . P ~n~uu~ouanai~ir~fmm~nr~~~~u~~~u2ts'dii0n~~~aann"iw'aniu~~ni~~sju~~a1~~m UW-d JuneynriJ~ivi ~ ~ ~ ~ ~ X ~ ~ W I ~ ~ G ~ ~ I W L L ~ ~ L ~ T J ~ . J ~ I U M I ~ ~ Q ~0u&~i~~aiults 'ninl~u%

- , j - .*+ : . g y ' . : : . : . I U _

' . - , k \ . , , I:: & . , ' f - . . -

HIV-1 Transmission Rate among infants born to ARV treated mother during 1 9 9 7 - 2 0 0 4 : A retrospective

study from Lab Network of DMSC.

A 4 2 u m ~ i wi~nw"naan~ inu i~n i~nn~" l~a~a l i ! a~ -~ <luau 15,000-20,000 nuiag duseiani3 1 n ~ ~ u a i n u i ~ n i ~ i n ~ ~ j ~ n " b ~ e r i 6 i u ~ ~ ? s ~ : u t ~ u m ~ n ~ a a n i s M ' u s d ~ G I n i ~ ~ & u ? n n i u ~ m ~ ~ n i ~ ? n ~$aainuilni@-~-m ~ i n l a ~ i m s ~ a m s ~ l s l a d 6 o s ~ o u i u 1 8 ileu$sssdwa!i' P, 9 ~ n ~ a s j i u h s d ~ % nl3n3uinuialnnim~bbww di 'w"wu1~n~iu i In-house HIV-PCR u ln ja i w.a 2 5 3 7 - & 9 h ?"a <~6 i i un i~d~ :~Zud~ :%~?%n iw1un~u~ Inu i i aw?ns~n~n~u i i r i u i i u~u 3 8 2 n j a e i i s i i < l v h a

OI 4d d 4 &' sann$asnuas ELISA LLR: GPA ?auac 100 uan~in<e~~s~iu im~aa%u~Gn~naunainui~ni '~~nn~aa i luKul~sw uiuia t~us3iud~:aiybn3izps" wui i i imiubnamaiu~i~wiz~pi~Ku 1 oo La: 9 5 d a b8nijuiq 6 iffuu 3qaljuLliuni3n32q~ui~nbdo?nniu~n34n~3anniabbw<b$aainbbi~tln Prevention

mother to child transmission (PMTCT) L&a%$ui~im~lba:?nniu~m3ini3~nb$a~6n3aun~u~n~u~ ~~3:~ds:h%wauusni3%$u16quI~ia~amAi'

2 5 4 7 - 3 ~ ? G ~ d ? u d T ~ ~ n ~ i u i % M ' ~ d 3 t ? n % n l ~ i ~ u ~ u 3lnl?nRJ ~ U ~ R S J T I I ~ PMTCT f u di~ns:uin~nud~n~dr:ssdlvi~lfm~naaun~u~n&t(%ud~:~w~~"bwu lnua rnh r 1,8uGsriuayu~n h u i & T w u i $nni=iIInauru Tmn7uun7niu6~aatnauquamniwnian3aa lnun3aab8nbi;;aiquinn<i 1 tau an:v+is~in$uin 2 Lieu ~daIi 'wamsa~d~n~~as

warnsdnai i . ~ u d ~ w.a 2537-2547 I6sCuayw~nwnaaulss"n"u~niaiier?d~~$a 20.000 amnmaau d * O I

iliiu2uy nainsn~siauni~~neusu~~~wua:disd~t~n~iuinnii 200 nu ~ n i a i i u s s " a ~ d ~ G i n 7 3 ? 6 ~ a ~ ? u d V d : ~ ~ ~ i ~ ~ a . ~ n r ~ n ~ ~ ~ a i a i r r n ~ u l w l n s ~ n i r PMTCT 6 2 a ~ i ~ w ~ n i 2 ~ n ~ i 1 1 a 1 n i a i i e r u m ~ ~

k a : > d

~ ; - . g ~ i - c ~ . : ; 1 : - ~ : 1 ~ . ~ 1 ~ j i ~ ~ ~ ~ ~ i ~ ~ ~ ~ g i ] ~ ~ 1 ~ n ~ ~ ~ ~ a ~ i . j ~ u ~ ~ - ~ . ~ j : ? ~ i . ~ ~ ~ 2 ~ ~ ~ G ~ ~ n i f ~ s s " e r i ~ q ~ ~ a ~ ~ . i P L 4' d

~ ~ ~ $ ~ - i : . ~ ~ - - ~ ~ : ~ . : i . : - - - ~ - ~ ; ~ ~ ~ ~ ~ i - : ~ . ; - ~ - ~ r r 7 : ; . ; - ~ ~ ; ~ ~ - 3 , : ~ ~ ~ : v a ~ ~ 3 1 n i ~ W ~ ~ g a l p d n ~ ~ b $ p , ~ n n . 2'

uq3fli~~:$~~l;a~.:-.::i~~: 23.8 i wuklII = j C f < .-h-:;F:-P-cr-t ? K c - - , < , adnnda~i"b?ueri GT 1~952~".7?= . . - , . . - C F ; I - i i $ i .~a : 5.5 ~ia: 2 I. 15 ~ iu i i i71 uanain

2 . . . - ~ ~ n i h 9 ~ 2 u n " E l ~ ~ i ~ ~ ~ i % i ~ i i 5 i ~ ~ T 5 ~ ~ ~ ~ ' 5 i ~ ~ ~ ~ ~ ' i i ; Zldovudine %:er:ib~dn%sni% PMTCT wurdi~w31 nisiionan~Ba~inui~~naw9~Lw~jii;iujiau9z 2,9 . j m r ~ n ~ u i ~ i ~ ~ ~ u e r i ~ ~ m ~ i n i ~ ~ n b ~ a i a u a z 14.3

a2daa t ie i sd inissi iu$sddfju~msnsaB HIV-PCR vadnsuf nuiflianfmsiiwn~muiinio~?lr u l u u i u u ~ ~ n s m a a ~ m a ~ s m ~ u l u T n 3 ~ n ~ s PMTCT aiw:ldiilu~n~s~iislun~sGn~~uds:2p?^bt-lauo.1 ~ n w n i s ~ ~ R i i l i r r u i u w n ~ ~ ~ i n i s ~ n a ~ a ~ u m ~ n h i m ~ a i v i u ~ i a u ~ t 3 u i d 1 d S d s : ~ n t n i n

~ @ r ~ i u u ~ u ~ n ~ i u i ~ 1 i ~ u ~ d ~ d ~ ~ d ~ n i 5 i ~ ~ ~ & ~ i n ~ i d d s : r n n ~ i 1 ~ b ~ u ~ w m ~ ~ i ~ i u i d w 8 ~ ~ ~ 1 f i a d ~

s m ~ p n n i q d ~ I o ivi~h i m : i i T e n ~ s ~ w u ~ ' i $ ~ n w ~ n < i b ~ u ~ ~ n ~ f ~ ~ ~ ~ ~ m n ~ s ~ ~ ~ i u u ~ n $ u i gh~ r - i ~u ~ i 3 ~ d ~ U ~ ~ ~ U ~ ~ ~ H ~ ~ ~ 2 i ~ ~ ~ n ~ ~ d ~ ~ l ~ ~ d d ~ ~ l ~ n 7 ~ 3 : ~ ~ % i ~ ~ R n i ~ 9 1 ~ H 9 ~ l ~ ~ 2 i 8 1 ! 2 b b ~ t ~ ~ i ~ ~ ~ l b ~ i : ~ ~ ~ ~ :

l o o (u2n 19 nu 81 ) raa:Zdst2n~niw~unis~s~u~.ii,u~un~aGna$saaa!a4'i'1bnisn~Gna~ai~ 6 r6vu

Staphylococcus aureus with resistance to vancomycin

u C.e P

nmum~ u2w u i ~ i i i n i ~ ~ ~ ~ 3 m y v n s u f n u ~ m a n i m s i r w n f i

antiT~atiaqdsra~ffuTnnT3wui$a MRSA wan21ubuiau1 vancomycin (VISA) ailun:jumdds:mpl

tjtuluq w.. 2539 ~ i I r i ~ ~ a n ~ u i i o n i ~ r r i ~ ~ ~ s ~ ~ u n i s ~ i w ~ n s : ~ i u " ~ a ~ i $ s aa:n is~nw[d~ud?a&

VISA ~ u d s : a n ~ b u 0 n u n u w ~ ~ a ~ s VISA nkusnIu9 W.R. 2544 lnu p s - m ~ i m~:t~naa~;3Nr LLR:RIU:

K s ~ d jn~n~~ai~lau1npJ"d!i!~d~1Qlan1sa~u5$naiia~ln~a~ VISA ri,lliquTnis&ut8aCsuuin ~ u i ' d i u P W P

klidn; amuu2ilu2nu~~liania~~i3blb~"~nsu~nu1~1a~~nisaaw91eJ"b~dn~ibba:b~7s:a"9~$0~l~~insrildiabiia~ era

-xn isZnw n a a r e u ~ C s aureus 862 a q u ~ u f & ~ m ~ ~ s u unmnu 2546 ad a ~ u ~ ~ u 2547

hB156lu ja?h 10 %En Amoxicilliniclavulanic acid (AMC), Clindamycin (CLI), Co-trimoxazole

(SXT), Erythromycin (ERY), Gentamycin (GEN), Oxacillin (OXA), PenicillinG (PEN), Vancomycin

(VAN), Fosfomycin (FOS) bba: Teicoplanin (TEI) 6'2ufZ disk diffusion (Kirby Bauer) ira:'Ml~l MlC

"~aderi Vancomycin Gauaaduuiiia?~=jd E-Test

t r a n i z ~ n a i wln0ub$u MRSAisua: 48.7 (420 m u k d ) aril: MSSA~CIUR: 5 1.3 (442 BTU

~ u f ) MRSA & i s AMC, CLI, SXT, ERY, FOS, GEN, -rEI u a t VAN faun: I 00. 38.8, 95. 97.1,

1 1.9, 91.7, 0.2 raw: 0 aiudi i 'u MSSA ~ouii 'dnii~niudii 'ur~u?auw: 1.6, 2.5, 2 , 4.5, 0, 1.4, A'

0.5 var o wuri~ MIC u m u ~ Vancomycin i saas S. aureus d n n s e u R r r u n a;a:~iv 0.5-3.0 p g i m l

% i s d ~ ~ a z a 2 d IL$B:U~!~WUL$~ VISA ~inni~ail i~:: jdi iuaJ~ L L ~ W U L & MRSA l$ii MIC u a ~ u i Z A

Vancomycin ;~$ud~ 3.0 pg/ml ~11%~ui~u21<un~sG%ui Vancomycin u s ~ ~ $ s t i u u u a ~ a : ~ i l u g n y ~ l u

n i s i n w ~ d i h u ! d w a u i m i s ~ ~ ~ ~ ~ n i m m s ~ n n i u n i ~ r ~ i u u a i ~ a ~ a i u ~ " u f a ~ s VISA deiuafinCis!d

m 3 p ~ ~ l M u ' a i l d ~ l u w " U ~ 3 t E l l ~ ~ W ~ " I I Z ) ~ L & I Vibrio parahaemolflicus 0 3 : K 6 l ~ d s r a n d n u

Emergence of the pandemic potential of Vibrio parahaemolyticus 0 3 : K 6 in 'Thailand

unhuat inqds:aan ' I J A S I R T S ~ S U G ~ U T ~ ~ ~ T $ T Z U L ~ B ~ ~ G U ~ ~ E I T L M ~ ~ T ~ L ~ ~ vibrio

parahaemolyticus ?d PI W.R. 2539 af innls%rulnJ1%~~ (pandemic)%u~aler ~ ) E ) ~ : ~ w R ~ I ~ ~ o ~ ~ ~ L ~ ~ : B P ~ < s ~ ~ ~ ~ ~ I 2 2 2

ain~Qnbbauaawi:wiuw"paf 03:K6 ~ i ~ i u d s r b n ~ ~ ~ u ~ n i s ~ ~ i n v a ~ s i ~ i s i i l ~ b ~ u a i n a ~ o z a a w u

' a

'S

C

P

2 .

c=

.

b5

.a

0

';

c

E

. E

W c

.- JZ

-8%

Q

:p

f

. -vs

8 .

g=

r

y

(a

.- '

(a

m

a"

.@

0

.$

, -c

2 a 5

:"

*

" 5

.@

%

'Z .

aa

. "e

.. ..

.- .-

- - .

oo

0

0

. .s r

.y .y

ti ti

.<

G

.0

0

.G

G

.o .o

'C

E

4 .

.- x X

.

oo

C

I C

'2

2

Q Q

C

I C

I '

EE

.

WW

'J C

2 E '0

G

F E J C 10 3

0

C

3

(C'

$ r P G

'0

G

9 5 c K-J

10 3 'i G

3. nl%m%asvlifiuim alkaline phosphatase

(AP) l$wni iauem:rn iaq~6uvass iaCi~ 6'1

~~haa$a bmuk3!d~~ww66s:~%us7nn7a.a"nda:a"G 4 . n i a a a a s w i d 5 u i m gamma-glutamyl

a 7 n x n ~ ~ u ~ i l u u ~ r i a u t k m a i n i a da:%rnal6?u transferase (GGT) ~gu~aul?iljndwuu?nd~~aBGu T R ~ U s~6sda:TGnialC?ua"am~~az~r :~~a:nau ~ ~ c i i a 7 s w u 1 ~ d a ~ a $ ~ ~ m $ u ~ a u ; s I ~ i i n a i u i 7 ~ w i c vasa:am niamraa! a i n i a n i u u a n + i ~ n i u n i a ~a7:wuinGn

5. nlamaaew7d?ulm albumin L f k 9 ~ 7 n A' dor

albumin ~~ubda~uWda5is"uuwmu $lei&uinaiut%

dnG d 5 u l m albumin %u~:oms:amas&n47dnG

nismsaqwi9amiimGGm adaso7n prothrombin ~3ubdsftuWdiaeih

1. n l s ~ s ~ s M l m ~ t n l s ~ n L ~ u " L I a 9 b g R ~ ~ ~ m a ~ ~ i s n i v a s ~ ~ a m $ s n i i s s i n n t ~ ~ a u A i n a ~ u n c i o r

bmermsaoM7d?u7mbaulg~ 2 "oGn lbaLi alanine ihdnmwmu s:Yii%~vlm prothrombin s:u:aaaind 2

aminotransferase (ALT) w?a serum glutamic pyruvic ~:amLb'&62 prothrombin time (PT) % U I ~ U I P ~ ~ U

transferase (SGPT) b~a: aspartate aminotransferase n i idn ;

(AST) w%~ serum glutamic oxaloacetic transaminase A

(SGOT) 1 ~ ~ % u n u d n ~ s : i d 1 a ~ a : w i i s 3 0 - 4 0 n i s n a a o w i s r ? i i < a 5 ~ i n u i

2. niamaaevlid5u7m bilirubin bhniamaas nina?uaiu7anvasKulun7an"7~ma7aWdIi i'asniapsKsj,,7n~Gm~$am~~msaamn % u n u d n G i d 7

~~uniamsaswiaia~~~uas6da:nauvasGa

L&~I~?K (antigen) wiaw7bdsduWd+~srnuahs A ' d vuLwamaunuasian7s~mb~a1a~R (antibody) jf ndtuulufisilui;$w~nnis Enzyme immunoassay

(EIA) $s in~ iu l aua :miu6 i~w7:~s d a n d i ~ u ? A P,

%:'MT679 antigen LLa: antibody "asvm:~!6l~sPdler

lu ld~mhuimaasf in3i :d i7~is2ddaiuian~i

b n u y n a i n s l u 6 s d i G m s ~ a s ~ i a l $ ~ n ' : a s i a

iTmbuGi gad w~nlud=xLnnbu i~s:Gi~hsin Laardek ailaasintJd~nuin t$a~a?a~uiYnLau.ii 24'

Fiiad~: LWFI i a u I w ~ s : n a i u ~ i l u $ ~ n ~ a a ~ s a ~ a n'9tuns8d

I. %a?aKuiYn~wu~a aiuiaomjlaawi m179WU Anti HCV 1 ~ b ~ a n ~ u ~ ~ l n ~ : L i ; l ~ ~ 9 n l a : A d 4'

~ii<uniruaaiianiudmauauaaiani-rin~$e 2 nu~saIun~:~~a~fian A d - i~a:muimnwi~~nnalum'

aQn IAa~ri Anti HAV I ~ M ~iiuniifur~ud=iianiu 1un~unuamnnis~n~8aii ueni~m-ras Anti HCV a > a5imuU%u~:u:aa~nuaania?n~aa Eiauannia: ibania~?lwwauandaau%G 8ana%iini%m%as

nis?na$ab5uuw$u sl"?maaswus:~~ana-dium: BuGuy n n u TnuIa'bnnQn Recombinant

~ u ~ i a m u f i i ~ a ~ i m s ? n b $ a ~ a ? ~ & u ~ n b a u b a a ~ ~ n t i immunoblot assay (RIBA) biluwiinm%dla' HCV

HAV total ab ~ i i u ~ i i ~ ~ u d i i a n i u a i i a 6 u l u encoded recombinant antigens aaa: synthetic pep- tides uuunu nitrocellulose nnswi antibody d =i:u:bb%n ~~a:a:u:w$auaanis?nb$a Ei~u en31

iianiu%Ga~iani6urYuia~$ala?a6u~n~~u~a <i~wi:ialaia&uiYn~auG ~ ~ i l s ~ r i u i ~ n h u i 91 9

6ua~a wesia~nulGYuTn.iiu"b?a&uiYn~au~auiriau d~ais~d~iw5"ElmsasduGu Anti HCV $iwdiu

n~$ni raQn~aiu isna~~Gmaan~d 4.la?aKugn~auGi %a7$msaswiqiifu;u

2. %a?a&uEn~aui aiui%nm.jap~idau ! 2 ? a $ ~ k b ~ ~ ~ %Gbbfi

2 ' " dsmauuaab$eua:~iifun"uiabaaw"aw~~~ 6 %En Anti HDV IgM Eiauannia:m%inb$ab~uuw~u

l6'bbfi H B S A ~ ~ilubd~ludauds:nauiiauaab$a Anti HDV total ab ~iauonnia:ni%inb$a

%a?a&uiYn~aud Liauanniacnis?na$a~5uuw$u L G U ~ W Kubba:Sa?a

sl"?m~a~wus:~~ana~ium:~ui ianiun" i$aini~ 5.!aia&uiYn~aut Iaifmsaswi~iqunir

?nL$ala?a6uiYnauda pi"sa~iluwiw:uaa~$a Anti la?a&uiYn~aut !Guri

~ B s ~ i l u ~ i { u h i a d a u ~ a v a s i < a ' b a ? a ~ u g n ~ a u h v

Anti HEV IgM Eisuonnia:ni%inb~ab~uuw$u a

d<isniua<iavu%u%:er:~a%nvasn7cj~n~$a Ei~uan Anti HEV IgG ~ ~ u ~ n ~ i i i ~ n - ~ n ~ n u ~ ~ i u ~ ~ a ~iiiamul~~5ia~ii~~nila?a&uiYn~aud~uuh h?aKugn~au8 uatiiiisqi7$'ur7&'ubbi'a

w~abnu~&?u~n~u%a?a&uiYnbau!uiriau Anti HBc 6. !a?a&u iYnaau8 %uusla:~~~~s'b~aiui%n

IgM bilu?iifuniaisdauununaia (core) uaab& ~ ~ u l i ~ m s n s ~ s n l a ~ l u 2 ~ ~ ~ ~ u ~ erl '4 a ~a<ianiua<iauu%u%:u:~~%n"~aani%in~$aEia

uan-dibia%&?uni%?na<a!a?a6uiYnbaud Anti HBc msmsaswiai~viuqnssuu aa ~$alaiaKu

total ~b Eisuannia:ni%~nb$ab5uuw$uwTa&a7a gnaau aaunis~ue~"unia:ni%~mb8a1~ biaasin

HBeAg ~ilubdsludauds:n auuas~$alaiaKu d~uimua~ai~Gu~n~~uua~18addua~~u~~anii ~uu inn i snc j a i3~aa Ia~~n i s~Au~ iuaumc j~"u~na~u

iYn"nud Liauannia:6~~an"iKaini%~~Eia6aiaf iu <luaua; ua:muisnuwif$um'nnti HBe Ei~~lan bnu%%wKnni% Polymerase Chain Reaction &w?u

A ~ A a, d d ~ r r " ~ , , - A , a b$a%a?a6uiYnbauba v m a 118:; bilula%avuai~j n~a:nis?nna~cja~a w'sauansZa~u~unun~nnuu

niu~%%uaiiw$sni%?n~~a vju;nnubiluaCn RNA b.rhai7nis RT PCR (Reverse

Transcription Polymerase Chain Reaction) %uni% 3. la?aKujmauGaiui~nn~as~i~ii(un"u biu<luaumlGuanslu daub$alaFa;ug nLau;

ia~$ala?a6uik~auG bnunsasm~nti HCV ;a bilula~aiislsGuqn33ub~uaGn DNA s:lGw;n iau%wnjbiluaGn IgG thmsapwua:Eisuan$a ,,, PCR (Polymerase Chain Reaction) bdabiu nia:ni%?nb$a~aaisb~u~~W"anis?n~$ab~uuw$u <iuaums$u;n%%u dauuea RNA wesia DNA d?n

~ i n ~ Z a n ~ ~ s ~ ~ u d ~ u i m a : ~ ~ a i u ~ ~ a n d i s n " p a % d Yba?ti6ugnbauc %6abn HBsAg , Anti HBs , ;Y d d d d

aiu.n~~yas~.na~a?H&l$nbR'Uba u q-j 9 aia:$ Anti HBc IgM , Anti HBc total , HBeAg , Anti Hbe , 8

tiiuisa7uasbs;iu RNA M%I DNA fibfiu<iua~dbb$a Yb~?ti6~%nbti~l$ Yb6bbfi Anti HCV

% n ~ n u n 1 3 ~ 1 agarose gel electrophoresis h % & ~ n ~ t i u G i ( nsaalawi:iJdauaiu6wu

~rh3ai i~Tnul%t i~sPasd~~t id ultraviolet %a?ti6ui"nbtiuc ) %6bbn Anti HDV IgM baa: Anti

HDV total nisam4uu~aoejidaAoddm~a~"a9~~uKa?a

4 '=4 ~ u ~ n ~ ~ u n i ~ ~ a d d ~ p 1 a n 1 5 %a?ti6ugnbtiui %6bafi Anti HEV IgM bbat Anti

HEV IgG i~w?uniaailaaawi~bninzGn I$~a i :~Zan

d ~ a u ~ i u a u 5 ijaggns Quuun~iiuiawi:.nau~wa ~a~6iG~"9'btia7ui~nisasaa%~~ufitiiuian

a f i u h a i i i s I ~ ~ a 5 u ~ ~ m ~ ~ ~ 4 asmaratQua i d a a a a ALT, AST, bil irubin abat alkaline

PI- d

phosphatase 6 i ~ d % ~ t i i ~ i ~ ~ ~ 3 ~ 9 ~ ~ ~ ~ ~ t i l ~ l 3 ~ n i s d ~ m s a s ~ i a i s ~ u ~ n s s ~ ~ a a ~ b<alaia61~15nbapJ

~f iu lu{abuqmm~i j 4 a ~ n i ~ . n a ~ Q u a aai:a$encjihu<iuau 5 ija88na Qinaun

di~?uniskaaaawi~~i j fun"u?w u i d~ A a6uaawiz.rrauawo6daaaa HAV RNA , HBV DNA,

1Qei:a8sn$diuSiraa11 5 ija88ma draa~un~nu d d

HCV RNA . HDV RNA . HEV RNA abac HGV RNA W V d C b a w i : . n a u b w ~ i ~ n a a s ~ a ; j i ~ 6 ~ l ~ n ~ w u ~ 0 I b ~ a n Anti L L s ~ l ~ , ~ u a 7 u l s n ~ d n a a ~ ~ ~ w ~ M n ~ l ~ l a n b6u1u

HAV IgM bbat Anti HAV total ab < L L ~ ; L $ J ~ W V @ - 2 0 ?oriaaaa$uti ~ " s e i i n i l

a%u$nsu?w u i~ i~m~n is~~wweJb

nwn6~Gjsu;si !!on'

UIU L L W W 63 i l8~~1~ b b i T 9 ? I 9 ~ ~

ns. Luiani wsw'qasam

uiseian3asani yfhra'

ns. 7erzn1 L93nJR5TWG

uisqsisd L*SIZ?LGW

ns. qos dinsiuuw'

ns. k u i (ailiiau'